Three questions, one set of capabilities.
Everything we do answers one of three questions: does it work, can it be built, and is the decision defensible? We carry a biobased or circular material from a lab result to a running plant — proving it on our own line before a euro of capital is committed.
Prove it
- Pilot & validation runsProving processes at scale on our own line before roll-out.
- Material & process R&DDeveloping and validating novel biobased materials, gate by gate.
- Feasibility & front-end engineeringA lab result turned into a costed, buildable process (FEL 1–3).
Build it
- Full EPCM deliveryEngineering, procurement and construction management — concept to commissioning.
- Fibre-route & feedstock engineeringField to mill gate — agrifibre and recovered-fibre routes for packaging.
- Used-equipment sourcing & relocationSound industrial assets found, verified, moved and re-integrated across borders.
- Circular & waste-to-value designRecovery, recycling and side-stream valorisation, engineered in.
Fund & decide it
- Technical & ESG due diligenceIndependent, first-principles validation of scale-ups and carbon claims, for capital.
- Ecosystem & funding designRegional platforms and EU-funded consortia, concept to submission.
- AI-assisted impact & market analysisScalable, data-driven intelligence for ecosystems, investors and corporates.
Bring your material. We take it from here.
Wherever you are — a lab result, a pilot, or a plan to scale — the first step is small, gated, and priced to let you in.
Scope
Tell us the material and where it needs to get to. We come back with a scoping note and a realistic plan.
Under NDA · no commitmentProve
We validate it on our own pilot line at Lemi — gate by gate, so you pay as you prove and can stop after any gate.
Start at a startup's budgetBuild
When the evidence holds, we engineer the scale-up — full EPCM, concept to a running plant, and stay to performance.
One team, end to endGood science isn't the bottleneck.
The crossing from lab to factory needs four things at once, and no single specialist carries them.
Proof
A lab result is not a production line. Without validation on real equipment, no buyer qualifies it and no investor backs it.
Engineering
Turning a process into a costed, buildable plant is a discipline most material innovators don't hold in-house.
Capital
Capital waits for de-risked evidence; evidence waits for capital. Ventures stall in the gap between the two.
Market
Even a proven material needs a route into a real supply chain — the mill, the converter, the brand that buys it.
Every material, sector, and border.
The constant isn't the material. The same method reaches from a founder's first gated pilot to a €280M mill, and from Finland to Latin America.
Materials
- Recyclable medical sterile packaging
- Textile-to-textile recycled fibre
- Agrifibre & recovered-fibre pulp
- Algae-derived pharmaceutical materials
- Mineral pigments & fillers
- Molded-fibre & dissolving pulp
For whom
- Material innovators & scale-ups
- Global FMCG brands & converters
- Impact funds & investors
- Cities, universities & ecosystems
- Industrial producers
- NGOs driving material transitions
Where
- Finland — engineering & pilot base
- Europe — core delivery region
- Asia — incl. India
- Latin America
- The Gulf / MENA · North America
- A new Nordics–Japan bridge